Company Description
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance.
In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions.
electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jun 22, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Daniel Goldberger |
Contact Details
Address: 200 Forge Way, Suite 205 Rockaway, New Jersey 07866 United States | |
| Phone | 973 290 0097 |
| Website | electrocore.com |
Stock Details
| Ticker Symbol | ECOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560258 |
| CUSIP Number | 28531P103 |
| ISIN Number | US28531P2020 |
| Employer ID | 20-3454976 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Daniel S. Goldberger | Chief Executive Officer and Director |
| Dr. Thomas J. Errico M.D. | Founder and Independent Director |
| Joshua S. Lev | Chief Financial Officer and Chief Strategy Officer |
| Michael Romaniw | Executive Vice President of Systems and Operations |
| Donald Melnikoff | Senior Vice President of Engineering, Regulatory and Compliance |
| Mitch Deshon | Vice President of Global Sales and Business Development |
| Michael Mansfield | Vice President of Marketing |
| Carrie Kochek | Senior Director of Human Resources |
| Dr. Peter S. Staats M.B.A., M.D. | Chief Medical Officer |
| Manuel A. Marques | Senior Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 6, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Aug 2, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 23, 2024 | 424B3 | Prospectus |
| Jul 22, 2024 | EFFECT | Notice of Effectiveness |
| Jul 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 17, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 17, 2024 | 8-K | Current Report |
| Jul 17, 2024 | UPLOAD | Filing |